PEG−Doxorubicin Conjugates: Influence of Polymer Structure on Drug Release, in Vitro Cytotoxicity, Biodistribution, and Antitumor Activity
- 14 May 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 16 (4), 775-784
- https://doi.org/10.1021/bc040241m
Abstract
Polymer−drug conjugates (polymer therapeutics) are finding increasing use as novel anticancer agents. Here a series of poly(ethylene glycol) PEG−doxorubicin (Dox) conjugates were synthesized using polymers of linear or branched architecture (molecular weight 5000−20000 g/mol) and with different peptidyl linkers (GFLG, GLFG, GLG, GGRR, and RGLG). The resultant conjugates had a drug loading of 2.7−8.0 wt % Dox and contained 50 value = 0.24 μg/mL). Biodistribution in mice bearing sc B16F10 tumors was assessed after administration of PEGs (5000, 10000, or 20000 g/mol) radioiodinated using the Bolton and Hunter reagent or PEG−Dox conjugates by HPLC. The 125I-labeled PEGs showed a clear relationship between Mw and blood clearance and tumor accumulation. The highest Mw PEG had the longest plasma residence time and consequently the greatest tumor targeting. The PEG−Dox conjugates showed a markedly prolonged plasma clearance and greater tumor targeting compared to free Dox, but there was no clear molecular weight-dependence on biodistribution. This was consistent with the observation that the PEG−Dox conjugates formed micelles in aqueous solution comprising 2−20 PEG−Dox molecules depending on polymer Mw and architecture. Although PEG−Dox showed greater tumor targeting than free Dox, PEG conjugation led to significantly lower anthracycline levels in heart. Preliminary experiments to assess antitumor activity against sc B16F10 in vivo showed the PEG5000linear (L)−GFLG−Dox and PEG10000branched (B)−GLFG−Dox (both 5 mg/kg Dox-equiv) to be the most active with T/C values of 146 and 143%, respectively. Free Dox did not show significant activity in this model (T/C = 121%). Dose escalation of PEG5000(L)−GFLG−Dox to 10 mg/kg Dox-equiv prolonged further animal survival (T/C = 161%). Using the Dox-sensitive model ip L1210 (where Dox displayed a T/C = 150% after single ip dose), the PEG5000(L)−GFLG−Dox displayed a maximum T/C of 141% (10 mg/kg Dox-equiv) using a once a day (×3) schedule. Further studies are warranted with PEG5000(L)−GFLG−Dox to determine its spectrum of antitumor activity and also the optimum dosing schedule before clinical testing.Keywords
This publication has 17 references indexed in Scilit:
- The dawning era of polymer therapeuticsNature Reviews Drug Discovery, 2003
- Effect of pegylation on pharmaceuticalsNature Reviews Drug Discovery, 2003
- HPMA Copolymers Platinates Containing Dicarboxylato Ligands. Preparation, Characterisation and In Vitro and In Vivo EvaluationJournal of Drug Targeting, 2002
- A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl)methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone, in human plasma and urine by reversed-phase HPLC with fluorimetric detectionJournal of Pharmaceutical and Biomedical Analysis, 1995
- A Branched Monomethoxypoly(ethylene glycol) for Protein ModificationBioconjugate Chemistry, 1995
- Light scattering and the absolute characterization of macromoleculesAnalytica Chimica Acta, 1993
- Drug-polymer conjugatesAnti-Cancer Drugs, 1992
- Preclinical evaluation of polymer-bound doxorubicinJournal of Controlled Release, 1992
- Polymers containing enzymatically degradable bonds, XII. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly [N-(2-hydroxypropyl)-methacrylamide] copolymer drag carriers in vitro and antitumour activity measured in vivoJournal of Controlled Release, 1992
- Effect of molecular weight (Mw) ofN‐(2‐hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to ratsJournal of Biomedical Materials Research, 1987